Scienture, LLC Receives New Patent for SCN-102, Expanding Intellectual Property for Innovative Losartan Liquid Formulation

Quiver QuantitativeDec 10 08:13 ET

Scienture, LLC, a Wholly Owned Subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering Its First Product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) Through 2041

GlobeNewswireDec 10 08:05 ET

Express News | Scienture, LLC, a Wholly Owned Subsidiary of Scienture Holdings, Inc. (Nasdaq: Scnx) Announces Issuance of a New Patent Covering Its First Product Scn-102 (Losartan Potassium Oral Suspension, 10Mg/Ml) Through 2041

ReutersDec 10 08:05 ET

Express News | Scienture Holdings Inc Files for Resale of up to 4.3 Mln Shares of Common Stock - SEC Filing

ReutersDec 4 10:42 ET

12 Health Care Stocks Moving In Monday's Pre-Market Session

BenzingaDec 2 16:05 ET

Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump

BenzingaDec 2 11:19 ET